NM_001243156.2(TAF1C):c.2287C>T (p.Pro763Ser) AND not specified
- Germline classification:
- Likely benign (1 submission)
- Last evaluated:
- Oct 31, 2022
- Review status:
- Somatic classification
of clinical impact: - None
- Review status:
- Somatic classification
of oncogenicity: - None
- Review status:
- Record status:
- current
- Accession:
- RCV004193847.1
Allele description [Variation Report for NM_001243156.2(TAF1C):c.2287C>T (p.Pro763Ser)]
NM_001243156.2(TAF1C):c.2287C>T (p.Pro763Ser)
Condition(s)
- Synonyms:
- AllHighlyPenetrant
- Identifiers:
- MedGen: CN169374
-
Sphyrapicus nuchalis isolate rnsa_SAB19 control region, partial sequence; mitoch...
Sphyrapicus nuchalis isolate rnsa_SAB19 control region, partial sequence; mitochondrialgi|1766757221|gb|MK689546.1|Nucleotide
-
Sphyrapicus nuchalis isolate rnsa_SAB17 control region, partial sequence; mitoch...
Sphyrapicus nuchalis isolate rnsa_SAB17 control region, partial sequence; mitochondrialgi|1766757219|gb|MK689544.1|Nucleotide
-
DA190266 BRAMY3 Homo sapiens cDNA clone BRAMY3012599 5', mRNA sequence
DA190266 BRAMY3 Homo sapiens cDNA clone BRAMY3012599 5', mRNA sequencegi|79166883|gnl|dbEST|33044331|dbj| 266.1|Nucleotide
-
CADTH Canadian Drug Expert Committee Recommendation: Latanoprostene Bunod (Vyzul...
CADTH Canadian Drug Expert Committee Recommendation: Latanoprostene Bunod (Vyzulta — Bausch Health, Canada Inc.)
Your browsing activity is empty.
Activity recording is turned off.
See more...Assertion and evidence details
Last Updated: Nov 10, 2024